Record Nr.	UNINA9910253860803321
Titolo	Human iPS Cells in Disease Modelling / / edited by Keiichi Fukuda
Pubbl/distr/stampa	Tokyo : , : Springer Japan : , : Imprint : Springer, , 2016
ISBN	4-431-55966-3
Edizione	[1st ed. 2016.]
Descrizione fisica	1 online resource (102 p.)
Disciplina	570
Soggetti	Stem cells
	Cell culture
	Stem Cells
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references at the end of each chapters.
Nota di contenuto	Chapter 1 Recent Improvements and Emerging Issues in iPSC Generation for the Modeling of Disease Chapter 2 Cardiomyopathy Chapter 3 Modelling Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy with Patient-specific iPSCs Chapter 4 Cardiac Arrhythmia Modelling Using iPS Cells Chapter 5 iPSC Disease Modeling of Laminopathies Chapter 6 Hematological Disorders Chapter 7 Inherited Metabolic Disorders of the Liver.
Sommario/riassunto	Human iPS cells have a great potential to be cell sources for regenerative medicine because of the promise of infinite self-renewal and the capability to differentiate into multiple cell types. This book focuses on another great potential of human iPS cells, which is the establishment of human disease models using patient-specific iPS cells. Human iPS cells can be easily obtained from a patient's somatic cells and provide the entire information on the patient's genome. Accordingly, we can generate disease models for inheritable diseases in cell culture dishes using iPS cells. This is a quite new technique but holds tremendous potential for our increased understanding of pathogenesis, and will then be the basis for novel drug development industries. All the authors are leading researchers in this field and they have reported many kinds of patient-derived iPS cells. In this book, they introduce the aspects that could be recapitulated in terms of

1.

disease modelling as well as further innovative findings such as novel pathogenetic insights and novel therapies.